Prophylactic Treatment With Oseltamivir

Not Applicable

Completed

• Conditions: Influenza, Human
• Interventions: Drug: Oseltamivir Oral Capsule for 10 days post-exposure; Drug: Oseltamivir Oral Capsule for 5 days post-exposure

• Registration Number: NCT03899571
• Lead Sponsor: University Medical Centre Ljubljana

Brief Summary

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-22
• Study First Submitted: 2019-03-31
• Study First Submitted QC: 2019-04-01
• Study First Posted: 2019-04-02
• Primary Completion: 2020-03-31
• Study Completion: 2020-03-31
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-02
• Last Update Posted: 2020-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 222

Inclusion Criteria

• 18 years or older
• exposure to influenza during hospitalization
• risk factors for influenza complications
• consent for participation obtained

Exclusion Criteria

• younger than 18 years
• hematological malignancy
• hospitalized in intensive care unit
• refusal to participate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
10 days	Oseltamivir Oral Capsule for 10 days post-exposure	oral oseltamivir 75 mg once daily for 10 days post-exposure
5 days	Oseltamivir Oral Capsule for 5 days post-exposure	oral oseltamivir 75 mg once daily for 5 days post-exposure

Primary Outcome Measures

Name	Time	Method
Occurrence of influenza like illness 10 days after oseltamivir prophylactic therapy	10 days after oseltamivir prophylactic therapy	Experiencing influenza like illness as self assessed by a patient and/or as assessed by a medical doctor while on prophylaxis with oseltamivir and during the following 10 days.

Trial Locations

Locations (1)

University Medical center Ljubljana; 🇸🇮 Ljubljana, Slovenia